Zobrazeno 1 - 8
of 8
pro vyhledávání: '"Leo W.-K. Cheung"'
Autor:
Kamaldeep Dhami, Anirban Chakraborty, Tarikere L. Gururaja, Leo W.-K. Cheung, Chaohong Sun, Felix DeAnda, XiaoDong Huang
Publikováno v:
Science signaling. 15(736)
The Bruton’s tyrosine kinase (BTK) inhibitor ibrutinib irreversibly binds BTK at Cys481, inhibiting its kinase activity and thus blocking transduction of B cell receptor (BCR) signaling. Although ibrutinib is durably effective in patients with B ce
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::68e1c9df287305535807f1cd52da6a5c
https://pubmed.ncbi.nlm.nih.gov/35639855
https://pubmed.ncbi.nlm.nih.gov/35639855
Autor:
Jan A. Burger, Tadeusz Robak, Fatih Demirkan, Osnat Bairey, Carol Moreno, David Simpson, Talha Munir, Don A. Stevens, Sandra Dai, Leo W. K. Cheung, Kevin Kwei, Indu Lal, Emily Hsu, Thomas J. Kipps, Alessandra Tedeschi
Publikováno v:
LEUKEMIA & LYMPHOMA
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname
Altres ajuts: Pharmacyclics LLC; AbbVie Company. Genomic abnormalities, including del(17p)/TP53 mutation, del(11q), unmutated IGHV, and mutations in BIRC3, NOTCH1, SF3B1, and XPO1 predict poor outcomes with chemoimmunotherapy in chronic lymphocytic l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::eb70d0ec4f57f3b08bf9d18fa4343b32
https://pubmed.ncbi.nlm.nih.gov/35337247
https://pubmed.ncbi.nlm.nih.gov/35337247
Autor:
Shiquan Wu, Shuo Ma, Shachar Peles, Israel Arango-Hisijara, Bernhard Hauns, Kevin A. Kwei, Franck Morschhauser, Elizabeth Chong, Morton Coleman, Graham P. Collins, Sven de Vos, Jacqueline C. Barrientos, Stephen D. Smith, Robert T. Chen, Peter Martin, Catherine Thieblemont, Christopher R. Flowers, Leo W.-K. Cheung, Ariela Noy
Publikováno v:
Blood advances. 4(22)
Advanced marginal zone lymphoma (MZL) is an incurable B-cell malignancy dependent on B-cell receptor signaling. The phase 2 PCYC-1121 study demonstrated the safety and efficacy of single-agent ibrutinib 560 mg/d in 63 patients with relapsed/refractor
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23c1b58f1fb2d03d2add57f55c2e2c56
https://pubmed.ncbi.nlm.nih.gov/35842643
https://pubmed.ncbi.nlm.nih.gov/35842643
Autor:
Ssucheng J. Hsu, Hsu-Ping Kuo, Darrin M. Beaupre, Sidney Hsieh, Mint Sirisawad, Matthias Versele, Mutiah Apatira, Chun-Te Chen, Betty Y. Chang, Karl J. Schweighofer, Leo W. K. Cheung, Scott A. Ezell, Karl Eckert
Publikováno v:
Molecular Cancer Therapeutics. 16:1246-1256
Diffuse large B-cell lymphoma (DLBCL) and follicular lymphoma are the most prevalent B-lymphocyte neoplasms in which abnormal activation of the Bruton tyrosine kinase (BTK)–mediated B-cell receptor signaling pathway contributes to pathogenesis. Ibr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::28b59b101b1465894ef664fdefcb0d95
https://doi.org/10.1158/1535-7163.mct-16-0555
https://doi.org/10.1158/1535-7163.mct-16-0555
Autor:
Dan Jones, Kevin A. Kwei, Adrian Wiestner, Danelle F. James, Leo W. K. Cheung, Jennifer A. Woyach, Inhye E. Ahn, James P. Dean, John C. Byrd, Susan O'Brien, Paolo Ghia, Carol Moreno, Elizabeth Chong
Publikováno v:
Blood. 136:32-33
Background : Ibrutinib (Ibr) is the only once-daily Bruton's tyrosine kinase (BTK) inhibitor with significant survival benefit vs chemo- and/or immunotherapy in multiple phase 3 studies of patients (pts) with CLL. Ibr in first-line (1L) CLL is associ
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::a751643a59c42a766fadd26be216915f
https://doi.org/10.1182/blood-2020-134386
https://doi.org/10.1182/blood-2020-134386
Autor:
Sandra Dai, Indu D. Lal, Fatih Demirkan, Talha Munir, David Simpson, Tadeusz Robak, Emily Hsu, Thomas J. Kipps, Leo W. K. Cheung, Alessandra Tedeschi, Don A. Stevens, Jan A. Burger, Osnat Bairey, Carol Moreno, Kevin A. Kwei
Publikováno v:
Blood. 136:25-26
Background Genomic abnormalities such as del(17p)/TP53 mutation, del(11q), and unmutated IGHV are risk factors that predict inferior outcomes with chemoimmunotherapy (CIT) in patients (pts) with CLL/SLL (Byrd J Clin Oncol 2006). Mutations in BIRC3, N
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::faede0318604423d81bc2c197b9b3fdd
https://doi.org/10.1182/blood-2020-134437
https://doi.org/10.1182/blood-2020-134437
Autor:
Karl J. Schweighofer, Betty Chang, Kamaldeep Dhami, Shiquan Wu, Jing Liu, Leo W. K. Cheung, Mint Sirisawad, Jeff Hsu, Hsu-Ping Kuo, Kevin A. Kwei, Chi-Ling Fu, Chia-Lin Hsu, Karl Eckert, Mutiah Apatira, Hugh Wang, Chun-Te Chen, Sidney Hsieh
Publikováno v:
Cancer Research. 77:4197-4197
Introduction: The cellular microenvironment plays a key role in the pathogenesis of B-cell malignancies (Amé-Thomas, Blood 2007; Podar, Leukemia 2009). Bone marrow stromal cell interactions can provide survival signals to CLL cells (Kurtova, Blood 2
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::afde9c343b20af2dc69d08a260ef7d04
https://doi.org/10.1158/1538-7445.am2017-4197
https://doi.org/10.1158/1538-7445.am2017-4197
Publikováno v:
Hawaii medical journal. 63(9)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::b38b0a13e2ae994b4034722793ab578e
https://pubmed.ncbi.nlm.nih.gov/15540527
https://pubmed.ncbi.nlm.nih.gov/15540527